IGNACIO VALDES: Open Payments
NPI 1760546360 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$65,830 in 247 payments from 19 companies in 2025. Trend: 2023 $13,379 · 2024 $20,861 · 2025 $65,830
Speaker / faculty: $51,766Consulting: $7,838Food & beverage: $4,937Travel & lodging: $1,289
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 49 | $25,609 |
| Teva Pharmaceuticals USA, Inc. | 56 | $21,859 |
| Otsuka America Pharmaceutical, Inc. | 40 | $16,275 |
| E.R. Squibb & Sons, L.L.C. | 24 | $417 |
| Alkermes, Inc. | 20 | $411 |
| Vanda Pharmaceuticals Inc. | 15 | $321 |
| Janssen Pharmaceuticals, Inc | 11 | $295 |
| Lundbeck LLC | 8 | $159 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
Products named: INGREZZA, UZEDY, ABILIFY MAINTENA, REXULTI, COBENFY, ARISTADA, FANAPT, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
